Combining microfluidics with machine learning algorithms for RBC classification in rare hereditary hemolytic anemia.

Journal: Scientific reports
PMID:

Abstract

Combining microfluidics technology with machine learning represents an innovative approach to conduct massive quantitative cell behavior study and implement smart decision-making systems in support of clinical diagnostics. The spleen plays a key-role in rare hereditary hemolytic anemia (RHHA), being the organ responsible for the premature removal of defective red blood cells (RBCs). The goal is to adapt the physiological spleen filtering strategy for in vitro study and monitoring of blood diseases through RBCs shape analysis. Then, a microfluidic device mimicking the slits of the spleen red pulp area and video data analysis are combined for the characterization of RBCs in RHHA. This microfluidic unit is designed to evaluate RBC deformability by maintaining them fixed in planar orientation, allowing the visual inspection of RBC's capacity to restore their original shape after crossing microconstrictions. Then, two cooperative learning approaches are used for the analysis: the majority voting scheme, in which the most voted label for all the cell images is the class assigned to the entire video; and the maximum sum of scores to decide the maximally scored class to assign. The proposed platform shows the capability to discriminate healthy controls and patients with an average efficiency of 91%, but also to distinguish between RHHA subtypes, with an efficiency of 82%.

Authors

  • Valeria Rizzuto
    Josep Carreras Leukaemia Research Institute (IJC), 08916, Badalona, Spain.
  • Arianna Mencattini
    Department of Electronic Engineering, University of Rome Tor Vergata, 00133, Rome, Italy.
  • Begoña Álvarez-González
    Institute for Bioengineering of Catalonia (IBEC), Barcelona Institute of Science and Technology BIST, 08028, Barcelona, Spain.
  • Davide Di Giuseppe
    Department of Electronic Engineering, University of Rome Tor Vergata, 00133, Rome, Italy.
  • Eugenio Martinelli
    Department of Electronic Engineering, University of Rome Tor Vergata, 00133, Rome, Italy.
  • David Beneitez-Pastor
    Red Blood Cell Disorders Unit, Hematology Department, Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology (VHIO), 08035, Barcelona, Spain.
  • Maria Del Mar Mañú-Pereira
    Rare Anemia Disorders Research line, Translational Research in Child and Adolescent Cancer, Vall d'Hebron Research Institute (VHIR), ERN-EuroBloodNet Member, 08035, Barcelona, Spain.
  • Maria José Lopez-Martinez
    Institute for Bioengineering of Catalonia (IBEC), Barcelona Institute of Science and Technology BIST, 08028, Barcelona, Spain. mlopezm@ibecbarcelona.eu.
  • Josep Samitier
    Institute for Bioengineering of Catalonia (IBEC), Barcelona Institute of Science and Technology BIST, 08028, Barcelona, Spain.